To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Kristie L. Kahl
Now a 10-year survivor of bone cancer, Dana Vaughns chose to triumph over his disease and joined Bristol-Myers Squibb on its Coast 2 Coast 4 Cancer ride.
Kristie L. Kahl
Dana Vaughns and his colleagues rode 3,000 miles across the U.S. in support of funding research for the V Foundation.
Debu Tripathy, M.D.
Where does hope lie when it comes to improving the treatment landscape for rare cancers?
Arlene Weintraub
A new drug can break the circuit of cancer-causing effects that develop when certain genes fuse.
Kristie L. Kahl
From hereditary cancer risk among twins to study findings in squamous cell carcinoma, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
The Food and Drug Administration approved Turalio to treat patients diagnosed with a group of rare, benign tumors.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to a new drug application for the accelerated approval of tazemetostat to treat metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Alexandra Guadagno
From today’s top performers and athletes to surprising findings about prostate cancer treatment, here’s what is making headlines in the cancer space this week. 
Gina Columbus and Kristie L. Kahl
The FDA’s Oncologic Drugs Advisory Committee voted in favor of the agency approving pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor – a rare, benign lesion that can be locally aggressive and often recurring.
Beth Fand Incollingo
The New York City chef dreamed of opening her own restaurant.

Sign In

Not a member? Sign up now!
Continue without login